|
|
Vol. 24.14 – 24 April, 2023
|
|
|
|
|
|
|
|
Scientists suggested a novel role for PUMILIO2 (PUM2) in MSC osteogenesis and highlighted the potential of PUM2 knockdown-MSCs in bone regeneration. Additionally, they showed that AAV9-siPum2 is a potential gene therapy for osteoporosis. [Journal Of Biomedical Science]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Investigators screened 219 patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were enrolled in clinical trials of either CD19 or CD19/CD22 CAR T-cell therapy.
[Blood Cancer Journal]
|
|
|
|
|
|
Scientists conducted a prospective study and evaluated the potential benefit of an earlier lymphopheresis on the clinical outcome of CD19-CART infused DLBCL patients, in comparison with standard lymphopoiesis.
[British Journal Of Haematology]
|
|
|
|
|
|
Researchers found that substantially reducing systemic tumor quantity using high-dose radiation to bulky disease, which is commonly done clinically, was less impactful on overall survival in mice achieved by CAR T cells than targeting all sites of disease with low-dose total tumor radiation prior to CAR T-cells.
[Blood Advances]
|
|
|
|
|
|
Neural progenitor cells transduced with glial cell line-derived neurotrophic factors were transplanted into the subretinal space of rats where they protected photoreceptors and vision, and the spinal cord of SOD1 rats where they protected motor neurons. [Stem Cell Reports]
|
|
|
|
|
|
Researchers revealed that Bruton tyrosine kinase inhibitors (BTKIs) preserved T-cell and CART19 functionality under persistent antigen exposure and further demonstrated that BTKI administration was a potential strategy for mitigating cytokine release syndrome after CART19 treatment.
[Cytotherapy]
|
|
|
|
|
|
Scientists presented a multicenter study on the safety and efficacy of MSC therapy for patients with steroid-refractory late steroid-refractory acute graft versus host disease (aGvHD) in comparison to those with aGvHD.
[Annals Of Hematology]
|
|
|
|
|
|
Investigators demonstrated that dendritic cell (DC) vaccines could promote CAR-T therapy in solid tumors, which provided the possibility of widespread clinical application of CAR-T cells in the future.
[Clinical And Translational Oncology]
|
|
|
|
|
|
Researchers investigated the feasibility and effectiveness of wound healing using decellularized HAM and stromal HAM (sAM) in combination with adipose-derived human mesenchymal stem cells (AdMSCs), and found that the combination promoted wound healing by enhancing angiogenesis and collagen remodeling. [Acta Histochemica]
|
|
|
|
|
|
|
|
The authors examine how the ability to generate diverse central nervous system cell types from stem cells, along with a deeper understanding of cell-type-specific functions and pathology, is advancing preclinical development of cell products for the treatment of neurodegenerative diseases.
[Cell Stem Cell]
|
|
|
|
|
|
Focusing on both large B cell lymphoma and multiple myeloma, investigators review resistance mechanisms, explore therapeutic avenues to overcome resistance to CAR T cell therapies, and discuss the management of patients who have relapsed after CAR T cell therapy. [Transplantation And Cellular Therapy]
|
|
|
|
|
|
|
|
Medigene AG reported final Phase I dose escalation results from the first-in-human study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy for high-risk myeloid and lymphoid neoplasms. [Medigene AG]
|
|
|
|
|
|
|
|
April 30 – May 5, 2023 Barga, Italy
|
|
|
|
|
|
|
|
|
|
|
Delft University of Technology – Delft, Netherlands
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|
|
Case Western Reserve University – Cleveland, Ohio, United States
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|